Represents the amount of potential payments upon achievement of post-approval and sales-based milestones.

No definition available.

Name:	fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents information pertaining to the number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones.

+ References

No definition available.

+ Details

Name:	fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones
Namespace Prefix:	fold_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

This element represents reimbursements for research and development costs under collaboration agreements.

+ References

No definition available.

+ Details

Name:	fold_ResearchRevenue
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Cash received from licensees for license fees during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=51671726&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=fold_GlaxoSmithKlinePLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=fold_RevisedCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=fold_BiogenIdecMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Agreements (Details) $ in Thousands	1 Months Ended	6 Months Ended	12 Months Ended
Collaborative Agreements (Details) $ in Thousands	Nov. 30, 2013 USD ($) item	Dec. 31, 2016 USD ($)	Dec. 31, 2014 USD ($)
Collaborative Agreements
Research revenue for work performed under cost sharing arrangement			$ 1,224
GSK \| Revised Agreement
Collaborative Agreements
Upfront payment received	$ 0
Potential milestone payments upon achievement of post-approval and sales-based milestones	$ 40,000
Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones \| item	8
Milestone revenue recognized		$ 500
Biogen Idec
Collaborative Agreements
Research revenue for work performed under cost sharing arrangement			$ 1,200